Bavarian Nordic AS (OCSE:BAVA) FFO


OCSE:BAVA Bavarian Nordic AS OCSE:BAVA
87 GF Score
Price kr185.00
GF Value kr165.20
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Bavarian Nordic AS FFO?

FFO (Funds from operations) only applies to REITs.

OCSE:BAVA
87GF Score
Bavarian Nordic AS OCSE:BAVA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bavarian Nordic AS (OCSE:BAVA) Overvalued in 2026?

Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued. The current stock price of kr185.00 is trading 12% above its estimated GF Value™ of kr165.20. GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.

Key valuation signals for OCSE:BAVA:

  • FFO:
  • GF Value™: kr165.20 vs. price of kr185.00 (12% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the OCSE:BAVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bavarian Nordic AS Business Description

Address Philip Heymans Alle 3, Hellerup, DNK, 2900
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
87GF Score

Get the complete analysis for OCSE:BAVA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr185.00
Price
kr165.20
GF Value